Trade Summary

Yesterday, Kaplan Andrew T., serving as Dir, 10% owner at Kailera Therapeutics, Inc. (KLRA), purchased 8,398,438 shares at $16.00 per share, for a total transaction value of $134,375,008.00. Following this transaction, Kaplan Andrew T. now holds 26,255,581 shares of KLRA.

This purchase represents a 47.00% increase in Kaplan Andrew T.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 20, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, meaning the disclosure happened on the same day as the trade.

Kailera Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.